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Abstract
Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis (M. tuberculosis), is a
major cause of morbidity and mortality worldwide and efforts to control TB are hampered by
difficulties with diagnosis, prevention and treatment 1,2. Most people infected with M.
tuberculosis remain asymptomatic, termed latent TB, with a 10% lifetime risk of developing active
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TB disease, but current tests cannot identify which individuals will develop disease 3. The
immune response to M. tuberculosis is complex and incompletely characterized, hindering
development of new diagnostics, therapies and vaccines 4,5. We identified a whole blood 393
transcript signature for active TB in intermediate and high burden settings, correlating with
radiological extent of disease and reverting to that of healthy controls following treatment. A
subset of latent TB patients had signatures similar to those in active TB patients. We also
identified a specific 86-transcript signature that discriminated active TB from other inflammatory
and infectious diseases. Modular and pathway analysis revealed that the TB signature was
dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-
γ and Type I IFNαβ signalling. Comparison with transcriptional signatures in purified cells and
flow cytometric analysis, suggest that this TB signature reflects both changes in cellular
composition and altered gene expression. Although an IFN signature was also observed in whole
blood of patients with Systemic Lupus Erythematosus (SLE), their complete modular signature
differed from TB with increased abundance of plasma cell transcripts. Our studies demonstrate a
hitherto under-appreciated role of Type I IFNαβ signalling in TB pathogenesis, which has
implications for vaccine and therapeutic development. Our study also provides a broad range of
transcriptional biomarkers with potential as diagnostic and prognostic tools to combat the TB
epidemic.
Blood transcriptional profiling has improved diagnosis and understanding of disease
pathogenesis 6-9. Such a comprehensive unbiased survey will provide insights into the
immunopathogenesis of TB, leading to advances in control of this complex disease.
Genome-wide transcriptional profiles were generated from blood from active TB patients
(before treatment), latent TB patients and healthy controls (Supplementary Fig. 1, Tables 1,
2). A distinct 393-transcript signature was defined in active TB patients (Training Set,
London), using a combination of expression level and statistical filters and hierarchical
clustering (Supplementary Fig. 2b(i), Table 3, Methods). We then applied the 393-transcript
list to two independent cohorts (UK Test Set; South African Validation Set). Hierarchical
clustering of transcriptional profiles showed active TB patients cluster independently of
latent TB and healthy controls, in both intermediate (London) and high burden (South
Africa) regions with a significant association between cluster and study group (Fisher's exact
test, p = 0.00001365, UK, Fig. 1a; and p = 5.79 × 10−10, South Africa, Fig. 1b). This was
independent of ethnicity, age or gender (Supplementary Figs. 2b(ii), c and d). The
transcriptional profiles of 10 – 25% of latent TB patients (5/21 Test Set, 3/31 Validation Set)
clustered with active TB patients (Fig. 1a, 1b). K-nearest neighbours class prediction using
the 393-transcript list, gave a sensitivity of 61.67%, specificity 93.75%, and an
indeterminate rate of 1.9% for the Test Set, (Supplementary Table 4), with 5 latent TB
patients classified as active TB and 4 active TB patients misclassified. In the Validation Set
the sensitivity was 94.12%, specificity 96.67%, and indeterminate rate 7.8%. The UK
patients were of diverse ethnicity, potentially infected with different M. tuberculosis
lineages, suggesting the signature may be independent of bacterial clade, although molecular
typing was not available. The proportion of latent patients having a transcriptional signature
similar to that of active TB was equal to the expected frequency of patients at risk of
progression to active disease 3, potentially identifying latent TB patients with sub-clinical
active disease or higher burden latent infection.
Four out of 21 active TB patients in the Test Set, also misclassified by class prediction,
clustered with healthy controls and latent TB patients (●, #, ■, ◆ Fig. 1a), demonstrating
molecular heterogeneity that could reflect clinical variance. To address this, radiographic
extent of disease was assessed by 3 physicians, blinded to clinical diagnosis and
transcriptional profile (Supplementary Fig. 3)10. The median “Molecular Distance to
Health”11, a composite of the number of transcripts in a profile that significantly differ from
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the healthy control baseline, and the degree of that difference for advanced disease, was
significantly higher than for those with minimal or no disease (Fig. 1c). We show for the
first time that the transcriptional signature in blood correlates with extent of disease in active
TB patients, and reflects changes at the site of disease. The transcriptional signature was
diminished in active TB patients after 2 months, and completely extinguished by 12 months
after treatment, with “Molecular Distance to Health” at 12 months significantly lower than
at baseline pretreatment (Fig. 1d and Supplementary Fig. 4), reflecting radiographic
improvement. Thus the blood transcriptional signature of active TB patients could be used to
monitor efficacy of treatment, and is reflective of the host response to M. tuberculosis
infection.
The 393-gene active TB signature may reflect common inflammatory responses evoked
during many diseases. We therefore identified a TB-specific 86-gene whole blood signature
through analysis of significance 12, compared to patients with other bacterial and
inflammatory diseases (Supplementary Fig. 5, Tables 5 and 6). This 86-gene signature was
then tested against patients normalized to their own controls from 7 independent datasets by
class prediction (K-nearest neighbours) (Fig. 2a). Sensitivities in the TB Training and
Validation Sets were 92% and 90% respectively, distinguishing active TB from other
diseases with a pooled specificity of 83% (Supplementary Table 7). As with the 393-gene
signature this 86-gene signature was diminished in response to treatment (Fig. 2b), and
reflected the same heterogeneity in identical patient samples (Supplementary Fig. 6).
To identify functional components of the transcriptional host response during active TB, we
employed a modular data mining strategy, using sets of genes that are coordinately
expressed in different diseases and defined as specific modules, often demonstrating
coherent functional relationships through unbiased literature profiling 7. The blood modular
signature of active TB patients as compared to healthy controls (filtering out only undetected
transcripts, α=0.01, in at least 2 individuals) was similar in all 3 TB datasets (Fig. 3a,
Supplementary Fig. 7), confirming the reproducibility of the transcriptional signature. The
modular TB signature revealed decreased abundance of B cell (Module, M1.3) and T cell
(M2.8) transcripts and increased abundance of myeloid related transcripts (M1.5 and M2.6).
The largest proportion of transcripts changing in a given module in TB, were within the
IFN-inducible module (M3.1; 75 - 82% of IFN-module transcripts; Fig. 3a). Since a Type I
IFN-inducible signature, linked with disease pathogenesis, has been demonstrated in PBMC
from patients with SLE 13,14, we compared whole blood modular signatures from patients
with other diseases. SLE patients demonstrated over-representation of the IFN-inducible
module (M3.1, Fig. 3a, quantitated in Supplementary Fig. 8), but displayed a plasma-cell
related module absent in TB (M1.1, Fig. 3a; Supplementary Fig. 8). The blood modular
signature from patients with Group A Streptococcus or Staphylococcus infection, or Still's
disease showed minimal to no change in the IFN-inducible module (M3.1) but marked over-
representation of the neutrophil-related module (M2.2), distinguishing these diseases from
TB (Fig. 3a, Supplementary Fig. 8). Thus the IFN-inducible signature is not common to all
inflammatory responses, but is preferentially induced during some diseases, potentially
reflecting protection or pathogenesis. Although SLE and TB share common inflammatory
components such as an IFN-inducible response, the overall pattern of transcriptional
changes (Fig. 3a) and their amplitude (Supplementary Fig. 8) distinguishes one disease from
another.
The TB blood transcriptional signature could represent altered cell composition or changes
in gene expression in discrete cellular populations. Percentages of CD4+ and CD8+ T cells
and B cells, assessed by flow cytometry were significantly diminished in active TB patients,
with reduced numbers of total and central memory CD4+ T cells (Fig. 3b; Supplementary
Figs. 9a and b), in keeping with previous studies 15. That the reduction in T cell transcripts
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revealed by the modular analysis (Fig. 3a) resulted from changes in cell numbers in the
blood, was further confirmed since expression of these transcripts in purified T cells from
the same individuals did not differ between TB patients and healthy controls
(Supplementary Fig. 9c). In contrast, the increase in myeloid transcripts (M1.5, M2.6, Fig.
3a) in the blood of active TB patients was not accounted for by changes in monocytes
(CD14+, CD16−) or neutrophils (CD16+, CD14−) although inflammatory monocytes
(CD14+, CD16+) were increased (Fig. 3c; Supplementary Fig. 10a), as in other diseases 16.
Increased abundance of myeloid transcripts was less pronounced in purified monocytes
(CD14+) (Supplementary Figure 10b), suggesting involvement of other cells.
Pathway analysis confirmed IFN signalling as the most significantly over-represented
pathway in the 393-gene signature (Fischer's Exact test, Benjamini-Hochberg multiple test
correction, p<0.0000001, Supplementary Fig. 11). Genes downstream of both IFN-γ and
Type I IFN α/β receptor signalling were significantly over-represented in blood from active
TB patients (Fig. 4a, b, c). IFN-α2a and IFN-γ proteins were not elevated in serum from
active TB patients, although the IFN-inducible chemokine CXCL10 (IP10) was
(Supplementary Fig. 11c, d, e).
Although IFN-γ is protective during immune responses to intracellular pathogens, including
mycobacteria 4,17,18, the role of Type I IFNαβ is less clear. Type I IFN signalling is crucial
for defense against viral infections but may be detrimental during bacterial 19, including
mycobacterial infections20,21. Absence of IFNαβ signalling in mice improved outcome
after infection with highly virulent 20-22 but not less virulent strains of M. tuberculosis 23.
Highly virulent strains of M. tuberculosis induce higher levels of Type I IFNs 20. There are
reports of TB reactivation during IFN-α treatment for hepatitis C viral infection 24. The
increase in Type I IFNαβ-inducible transcripts in the blood of active TB patients (Fig. 4c),
correlating with disease severity, provides the first data in human disease to support a role
for Type I IFNs in TB pathogenesis. These IFN-inducible transcripts were over-expressed in
purified blood neutrophils and to a lesser extent monocytes, but not CD4+ and CD8+ T cells,
from active TB patients, compared to healthy controls (Fig. 4d; OAS1, IFI6, IFI44, IFI44L,
OAS3, IRF7, IFIH1, IFI16, IFIT3, IFIT2, OAS2, IFITM3, IFITM1, GBP1, GBP5, STAT1,
GBP2, TAP1, STAT1, STAT2, IFI35, TAP2, CD274, SOCS1, CXCL10, IFIT5).
Neutrophils are the predominant cell type infected with rapidly replicating M. tuberculosis
in TB patients 25. Evidence from genetically susceptible mice suggests that neutrophils
contribute to pathology during M. tuberculosis infection 26. Our studies support a role for
neutrophils in TB pathogenesis, which may result from over-activation by IFN-γ and Type I
IFNs.
Earlier microarray studies, limited by small numbers of patients and custom microarrays,
reported a small number of genes in blood associated with TB 27,28. Here we provide the
first complete description of the human blood transcriptional signature of TB. The signature
of active TB, observed in 10 – 20% of latent TB patients, may identify those individuals
who will develop active disease, facilitating targeted preventative therapy, but longitudinal
studies are needed to assess this. That the TB signature is dominated by Type I IFN-
signalling and reflects extent of lung disease, may indicate the process leading to disease
susceptibility. These data improve our understanding of the fundamental biology of TB and
may offer future leads for diagnosis and treatment.
METHODS SUMMARY
Whole blood was collected into Tempus tubes (Applied Biosystems, CA, USA) from active
TB patients (confirmed by culture for M. tuberculosis); Latent TB patients (defined by a
positive tuberculin-skin test (TST) (London) and/or a positive M. tuberculosis antigen-
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specific IFN-γ release assay, IGRA; healthy controls (recruited in London; TST/IGRA
negative). RNA was extracted from whole blood and purified (by Dynabeads, Invitrogen)
neutrophils, monocytes, CD4+ and CD8+ T cells and genome-wide transcriptional profiles
were generated using Illumina HT12 beadarrays, and analysed using Genespring GX, (see
main Methods section). Calculation of “Molecular Distance to Health” 11, transcriptional
modular analysis 7, and analysis of significance 12 were performed as previously described.
Pathway analysis was performed using Ingenuity (Ingenuity Systems, Inc., CA, USA).
Multiplex Serum Protein Measurement was performed using Milliplex Multi-Analyte
Profiling System by Millipore UK, Ltd, Dundee. Flow Cytometry was performed on a
Beckman Coulter Cyan using Summit Software Version 3.02, followed by FlowJo analysis.
METHODS (for online publication)
Participant Recruitment and Patient Characterization
The local Research Ethics Committees at St. Mary's Hospital London, UK (REC 06/
Q0403/128) and University of Cape Town, Cape Town, Republic of South Africa (REC
012/2007) approved the study. All participants were aged over 18 years old and gave written
informed consent. Participants were recruited from St. Mary's Hospital and Hammersmith
Hospital, Imperial College Healthcare NHS Trust, London, UK, Hillingdon Hospital, The
Hillingdon Hospitals NHS Trust, Uxbridge, UK and the Ubuntu TB/HIV clinic, Khayelitsha,
Cape Town, South Africa. Patients were prospectively recruited and sampled, before any
anti-mycobacterial treatment was initiated, but only included in the final analysis if they met
the full clinical criteria for their relevant study group. A subset of active TB patients
recruited into the first cohort recruited in London was also sampled at 2 and 12 months after
the initiation of therapy. Patients who were pregnant, immunosuppressed, or who had
diabetes, or autoimmune disease were ineligible and excluded from this study. In South
Africa, all participants had routine HIV testing using the Abbott Determine® HIV1/2 rapid
antibody assay test kit (Abbott Laboratories, Abbott Park, Illinois, USA). Active TB patients
were confirmed by laboratory isolation of M. tuberculosis on mycobacterial culture of a
respiratory specimen (either sputum or bronchoalvelolar lavage fluid) with sensitivity testing
performed by The Royal Brompton Hospital Mycobacterial Reference Laboratory, London,
UK or The Reference Lab of the National Health Laboratory Service, Groote Schuur
Hospital, Cape Town. In the UK, latent TB patients were recruited from those referred to the
TB clinic with a positive TST, together with a positive result using an IGRA. Latent TB
participants in South Africa were recruited from individuals self-referring to the voluntary
testing clinic at the Ubuntu TB/HIV clinic, and IGRA positivity alone was used to confirm
the diagnosis, irrespective of TST result (although this was still performed). Healthy control
participants were recruited from volunteers at the National Institute for Medical Research
(NIMR), Mill Hill, London, UK. To meet the final criteria for study inclusion healthy
volunteers had to be negative by both TST and IGRA.
Tuberculin Skin Testing
This was performed according to the UK guidelines 29 using 0.1ml (2TU) tuberculin PPD
(RT23, Serum Statens Institute, Copenhagen, Denmark). A positive TST was termed ≥6mm
if BCG unvaccinated, ≥15mm if BCG vaccinated, as per the UK national guidelines 30.
Interferon Gamma Release Assay Testing
The QuantiFERON® Gold In-Tube assay (Cellestis, Carnegie, Australia) was performed
according to the manufacturers instructions.
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Total and Differential Leucocyte Counts
2mls of whole blood was collected into Terumo Venosafe 5ml K2-EDTA tubes (Terumo
Europe, Leuven, Belgium). Samples were then analysed within 4 hours using the Nihon
Kohden MEK-6400 Automated Hematology Analyzer (Nihon Kohden Corporation, Tokyo,
Japan).
Assessment of Radiographic Extent of Disease
Plain chest radiographs were obtained for all patients recruited in London as digital images
and graded by three independent clinicians, blinded to the transcriptional profiles and the
clinical data, using a modified version of the classification system of the U.S. National
Tuberculosis and Respiratory Disease Association 10. This system characterises the
radiographic extent of disease into “Minimal”, “Moderately advanced” or “Far advanced”
stages, according to criteria based upon the density and extent of lesions and presence of
absence of cavitation. We modified the system for use in our study so that it also included a
classification of “No disease, and accounted for the presence of pleural disease or
lymphadenopathy. The system was then converted into a decision tree to aid classification
(Supplementary Figure 3a).
RNA Sampling, Extraction and Processing for Microarray Analysis
3mls of whole blood was collected into Tempus tubes (Applied Biosystems, Foster City,
CA, USA), vigorously mixed immediately after collection, and stored between −20°C and
−80°C before RNA extraction. RNA was isolated from Training Set samples using 1.5mls
whole blood and the PerfectPure RNA Blood kit (5 PRIME Inc, Gaithersburg, MD, USA).
Test and Validation (SA) Set samples were extracted from 1ml of whole blood using the
MagMAX™-96 Blood RNA Isolation Kit (Applied Biosystems/Ambion, Austin, TX, USA)
according to the manufacturer's instructions. 2.5mg of isolated total RNA was then globin
reduced using the GLOBINclear™ 96-well format kit (Applied Biosystems/Ambion, Austin,
TX, USA) according to the manufacturer's instructions. Total and globin-reduced RNA
integrity was assessed using an Agilent 2100 Bioanalyzer showing a quality of RIN of 7 –
9.5 (Agilent Technologies, Santa Clara, CA, USA). RNA yield was assessed using a
Nanodrop 1000 spectrophotometer (NanoDrop Products, The rmo Fisher Scientific Inc,
Wilmington, DE, USA). Biotinylated, amplified antisense complementary RNA targets
(cRNA) were then prepared from 200 - 250ng of the globin-reduced RNA using the Illumina
CustomPrep RNA amplification kit (Applied Biosystems/Ambion, Austin, TX, USA).
750ng of labelled cRNA was hybridized overnight to Illumina Human HT-12 BeadChip
arrays (Illumina Inc, San Diego, CA, USA), which contain more than 48,000 probes. The
arrays were then washed, blocked, stained and scanned on an Illumina BeadStation 500
following the manufacturer's protocols. Illumina BeadStudio v2 software (Illumina Inc, San
Diego, CA, USA) was used to generate signal intensity values from the scans.
Separated cells isolation and RNA extraction
Whole blood was collected in EDTA. Neutrophils (CD15+), monocytes (CD14+), CD4+ T
cells and CD8+ T cells were isolated sequentially using Dynabeads according to
manufacturers instructions. RNA was extracted from whole blood (5′ Prime Perfect Pure
kit) or separated cell populations (Qiagen RNEasy Mini Kit) and stored at −80°C until use.
Microarray Data Analysis
Normalisation—Illumina BeadStudio v2 software was used to subtract background, and
scale average signal intensity for each sample to the global average signal intensity for all
samples, except for Figure 5 and Supplementary Figures 5c and 6b, where signals are
normalised to the median of the control. A gene expression analysis software program,
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GeneSpring GX, version 7.1.3 (Agilent Technologies, Santa Clara, CA, USA, hereafter
referred to as GeneSpring), was used to perform further normalisation. All signal intensity
values less than 10 were set to equal 10. Next, per-gene normalisation was applied, by
dividing the signal intensity of each probe in each sample by the median intensity for that
probe across all samples. These normalised data were used for all downstream analyses
except the assessment of molecular distance to health detailed below.
Filtering—Using GeneSpring, all transcripts were filtered first to select detected
transcripts; those called present in greater than 10% of all samples. Present calls are selected
if the signal precision is <0.01. The remaining transcripts are filtered to select the most
variable probes - those that have a minimum of 2-fold expression change compared to the
median intensity across all samples, in greater than 10% of all samples.
Unsupervised analysis: hierarchical clustering and class discovery—This
approach aims to create an unbiased grouping of samples on the basis of their molecular
profiles, independently of any other phenotypic or clinical classification. Transcripts
meeting the filtering criteria are then subjected to hierarchical clustering using GeneSpring.
For hierarchical clustering of genes, we use a clustering algorithm based upon Pearson
correlation, creating a vertical dendrogram of genes, where transcripts with a similar
expression pattern across all samples are grouped together. The distances between branches
of the tree relate to the similarity of the expression patterns, and the distance between
clusters is determined by the average of the distance between all points in each cluster,
known as average linkage. The vertical expression profiles so generated can then be
subjected to the same hierarchical clustering algorithm, now grouping individual participants
into horizontally presented clusters on the basis of the similarity of their expression profiles.
For this stage, we base the clustering algorithm on Spearman Rank correlation. By
examining the cluster membership we can assess both whether the samples are grouping
according to known factors (clinical diagnosis, demographic features) and also discover if
there are unknown subclasses within the dataset.
Supervised analysis: statistical filtering and class comparison—The aim of the
supervised analysis is to identify transcripts which are differentially expressed between
study groups and that might serve as classifiers or yield insight into immunopathogenesis,
i.e. class comparison. The filtered list of transcripts generated for unsupervised analysis was
used as the starting point for the supervised analysis, i.e. those transcripts that were both
detected, and had at least 2 fold change in expression compared to the median, in greater
than 10% of all samples. Using GeneSpring, these transcripts were then tested using the
Kruskal-Wallis test for comparisons across all study groups, with a=0.01. Adjustment for
multiple testing was applied using the Benjamini-Hochberg False Discovery Rate (FDR) set
at 1%. Lists of transcripts generated in this way were then used for hierarchical clustering as
described above. Interpretation of functional roles of individual transcripts was established
by searching the database at the National Center for Biotechnology Information Gene
database at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene
Class Prediction—We utilised one of the class prediction tools available within
GeneSpring. The prediction model employed the K-nearest neighbours algorithm, with 10
neighbours and a p value ratio cut off of 0.5. All genes from the 393 transcript list were used
for the prediction. The prediction model was refined by cross-validation on the training set,
with the one Active outlier excluded. This model was then used to predict the classification
of the samples in the independent Test and Validation Sets. Where no prediction was made,
this was recorded as an indeterminate result. Sensitivity, specificity and 95% confidence
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intervals (95% CI) were determined using GraphPad Prism version 5.02 for Windows. P-
values were determined using two-sided Fisher's Exact test
Supervised analysis: (i) “Molecular Distance to Health”—This technique was
performed as previously described11. It aims to convert transcript abundance values into a
representative score indicating the degree of transcriptional perturbation of a given sample
compared to a healthy baseline. This is performed by determining whether the expression
values of a given sample lie inside or outside two standard deviations from the mean of the
healthy controls.
Supervised analysis: (ii) Pathway analysis—Additional functional analysis of
differentially expressed genes was performed using Ingenuity Pathways Analysis
(Ingenuity® Systems, Inc., Redwood, CA, USA, www.ingenuity.com). Canonical pathways
analysis identified the pathways from the Ingenuity Pathways Analysis that were most
significantly represented in the dataset. The significance of the association between the
dataset and the canonical pathway was measured using Fisher's Exact test to calculate a p-
value representing the probability that the association between the transcripts in the dataset
and the canonical pathway is explained by chance alone, with a Benjamini-Hochberg
correction for multiple testing applied. The program can also be used to map the canonical
network and overlay it with expression data from the dataset.
Supervised analysis: (iii) Transcriptional modular analysis—This analysis was
performed as described previously7,11. In the context of the present study, since the
modular framework was derived using Affymetrix HG U133A&B GeneChips, it was
necessary to translate the probes comprising the modules into their equivalents on the
Illumina platform. RefSeq IDs were used to match probes between the Affymetrix HG U133
and Illumina HT-12 V3 platforms. Unambiguous matches were found for 2,109 out of the
5,348 Affymetrix probe sets, and these were used in the present modular analysis. The
matching probes were preserved in their original modules. To graphically present the global
transcriptional changes, for the disease group as a whole versus the healthy control group as
a whole, spots are aligned on a grid, with each position corresponding to a different module
based on their original definition. Spot intensity indicates the percentage of differentially
expressed transcripts changing in the direction shown, from the total number of transcripts
detected for that module, while spot colour indicates the polarity of the change (red = over-
represented, blue = under-represented).
Significance Analysis12—Transcriptional changes in whole blood were evaluated
through statistical group comparison performed systematically for active TB (Test Set),
Staphylococcus infection, Still's syndrome, and adult and pediatric SLE versus their
respective healthy controls, which allows the normalization of each disease group to its own
matched healthy control group, thus avoiding biological or technical confounding factors. A
TB-specific whole blood signature composed of 86 genes was identified (Supplementary
Fig. 5 and Table 5 and 6, p<0.01) not in the four other datasets (p>0.05) using Mann-
Whitney T-Test with Benjamini and Hochberg False Discovery Rate multiple testing
correction. Class prediction was performed using K-Nearest Neighbors algorithm, as before.
Multiplex Serum Protein Measurement
1 – 4ml blood was collected into serum clot activator tubes (either Greiner BioOne 1ml
vacuette tubes, ref 454098, Greiner BioOne, Kremsmünst, Austria; or BD 4ml vacutainer
tubes, ref 368975; Becton Dickinson). Tubes were centrifuged at 2000g for 5 minutes at
room temperature and the serum portion extracted and frozen at −80°C pending analysis.
Analysis was performed by multiplexed cytokine bead-based immunoassay by Millipore UK
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(Millipore UK Ltd, Dundee, UK) using the Milliplex® Multi-Analyte Profiling system
(Millipore, Billerica, MA, USA). The serum levels of 63 cytokines, chemokines, soluble
receptors, growth factors, adhesion molecules and acute phase proteins were measured in
this way in each sample. Samples were assayed for levels of MMP-9, C-reactive protein,
serum amyloid A, EGF, Eotaxin, FGF-2, Flt-3 Ligand, Fractalkine, G-CSF, GM-CSF, GRO,
IFN-a2, IFN-g, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IL-1a ̤, IL-1b, IL-1Ra, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, CXCL10 (IP10), MCP-1, MCP-3, MIP-1 a, MIP-1b,
PDGF-AA, PDGF-AB/BB, RANTES, soluble CD40 ligand, soluble IL-2RA, TGF-a, TNF-
a, VEGF, MIF, soluble Fas, soluble Fas Ligand, tPAI-1, soluble ICAM-1, soluble VCAM-1,
soluble CD30, soluble gp130, soluble IL-1RII, soluble IL-6R, soluble RAGE, soluble TNF-
RI, soluble TNF-RII, IL-16, TGF-b1, TGF-b2 and TGFb-3.
Flow Cytometry
200μl of whole blood (collected in Sodium-Heparin tubes) per staining panel was incubated
with the appropriate antibodies for 20 minutes at room temperature in the dark. Red blood
cells were then lysed using BD FACS lysing solution (BD Biosciences), incubating for 10
minutes at room temperature in the dark. Cells were spun down and washed in 2ml FACS
buffer (PBS/ BSA/ Azide) before being fixed in 1% paraformaldehyde. Samples were then
run on a Beckman Coulter Cyan using Summit Software Version 3.02. Analysis was carried
out using FlowJo Version 8.7.3 for Macintosh (Tree Star, Inc.). Gating strategies used are
set out in Supplementary Figures 9 and 10. Flow cytometric data is presented as dot plots
(Figures 3, and Supplementary 9 and 10). Where appropriate pooled flow cytometry data
was tested for significance using the Mann-Whitney Rank Sum U-test. All antibodies were
purchased from BD Pharmingen or Caltag Laboratories (Invitrogen) except for CD45RA,
which was purchased from Beckman Coulter.
Statistical Analysis
Molecular distance to health and Modular Framework analysis calculations were performed
using Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA, USA). Statistical
analysis of continuous variables and correlation analysis was performed using GraphPad
Prism version 5.02 for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com). Analysis of categorical variables was performed using SPSS version
14 for Windows (Chicago, Illinois, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A distinct whole blood 393-gene transcriptional signature of active TB
393-transcripts differentially expressed in whole blood of active and latent TB patients and
healthy controls a, Test Set. b, Validation Set (SA) profiles, ordered by hierarchical
clustering (Spearman correlation with average linkage) creating a condition tree, upper
horizontal edge of heatmap; study grouping (clinical phenotype) coloured blocks at each
profile base. Heatmap rows = genes, columns = participants. c, Profiles were grouped
according to radiographic extent of disease and the mean “Molecular Distance to Health”
compared between groups (Methods) (Kruskal-Wallis ANOVA, Dunn's multiple
comparison, *** = p <0.0001). d, Active TB patients at 0, 2 and 12 months after initiation of
anti-mycobacterial treatment. The mean “Molecular Distance to Health” for each timepoint
was compared (Friedman's repeated measures test, Dunn's multiple comparison). Horizontal
bars indicate the median, 5th and 95th percentiles.
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Figure 2. A distinct whole blood 86-gene transcriptional signature of active TB is distinct from
other diseases
a, Comparison of 86-gene signature in patients with TB and other diseases normalized to
their own controls; TB (Training, n=13; Control, n=12), TB (SA, n=20; Control = 12),
Group A Streptococcus (Strep; n=23; Control=12), Staphylococcus (Staph; n=40; Control=
12), Still's disease (Still; n=31; Control=22), Adult (SLE; n=29; Control= 16) and paediatric
SLE (pSLE; n=49; Control=11) patients. b, Expression levels of 86 gene signature after 2
and 12 months of treatment in TB patients.
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Figure 3. Whole blood transcriptional signature of active TB reflects distinct changes in cellular
composition and gene expression
a, Gene expression (disease versus healthy controls) of TB (Test Set) and different diseases
mapped within a pre-defined modular framework. Spot intensity (red = increased, blue =
decreased) indicates transcript abundance. Functional interpretations previously determined
by unbiased literature profiling shown by colour-coded grid. Whole blood (Test Set active
TB patients and controls) analysed by flow cytometry for (b) CD3+CD4+ and CD3+CD8+ T
cells and CD19+CD20+ B cells (c) CD14+ monocytes, CD14+CD16+ inflammatory
monocytes and CD16+ neutrophils. Error bars = median, ** = p<0.01, * = p<0.05, Mann-
Whitney test.
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Figure 4. Interferon-inducible gene expression in active TB
Ingenuity Pathways analysis canonical pathway for interferon signalling symbol indicates
gene function (legend on right). Transcripts over-represented in Test Set active TB patients
shaded red a, Type II IFN-γ. b, Type I IFNαβ signalling. Transcript abundance of
representative IFN-inducible genes in active TB (Test Set) from c, whole blood, d, separated
blood leucocyte population. Transcript abundance/expression is normalised to the median of
the healthy controls.
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